Clinical Trials Logo
  1. Home
  2. Pharmacokinetics
  3. NCT01002378
  4. Details
NCT01002378 Clinical Trial

The Effect of Food (High Fat and Low Fat Breakfast) on the Pharmacokinetics of Regorafenib

Pharmacokinetics Clinical Trial

Official title:
A Phase I, Randomized, Open Label, 3-Way Cross-Over Study to Determine the Effect of a High-Fat Breakfast, a Low-Fat Breakfast and Fasting State on the Pharmacokinetics of a Single Oral Dose of 160 mg Regorafenib (BAY73-4506) in Healthy Volunteers

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT01002378
Other study ID # 14656
Secondary ID
Status Completed
Phase Phase 1
First received October 26, 2009
Last updated May 21, 2013
Start date October 2009
Est. completion date February 2010

Study information
Verified date May 2013
Source Bayer
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

An open label, three way crossover study to determine the effect of a high fat breakfast or a low fat breakfast on the pharmacokinetics of a single dose of regorafenib.

Recruitment information / eligibility
Status Completed
Enrollment 24
Est. completion date February 2010
Est. primary completion date February 2010
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

- Healthy male subject

- Age: 18 to 45 years (inclusive) at the first Screening examination

- BMI: between 18 and 32 kg / m²

Exclusion Criteria:

- Regular use of medicines at the time of Screening, including prescription medications, herbal supplements and high dose vitamins

- Sitting systolic BP > 140 mmHg or Diastolic BP > 90 or < 60 mmHg

- History of hypersensitivity or allergy

- History of somatic or psychiatric disease/condition, which may interfere with the objectives of the study

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Screening

Related Conditions & MeSH terms

Intervention

Drug:
• Regorafenib (Stivarga, BAY73-4506)
A single dose of regorafenib will be administered immediately following a high fat breakfast
• Regorafenib (Stivarga, BAY73-4506)
A single dose of regorafenib will be administered immediately following a low fat breakfast
• Regorafenib (Stivarga, BAY73-4506)
A single dose of regorafenib will be administered following an overnight fast

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Bayer

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Primary PK parameters: AUC, Cmax of BAY 73-4506 Samples up to 336 hours post dose No
Secondary Sec. PK Parameters: tmax and t1/2 of BAY73-4506 Samples up to 336 hours post dose No
Secondary AUC, Cmax, tmax and t1/2 of Metabolites Samples up to 336 hours post dose No
See also
  Status Clinical Trial Phase
Completed NCT04092725 - Study to Evaluate the Effect of SCY-078 on the PK of Dabigatran in Healthy Subjects Phase 1
Completed NCT04181008 - Pharmacokinetics of Amiloride Nasal Spray in Healthy Volunteers Early Phase 1
Active, not recruiting NCT03258151 - Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
Completed NCT04406415 - Oral Nafamostat in Healthy Volunteers Phase 1
Not yet recruiting NCT05421312 - Periarticular Penetration of Cefazolin and Clindamycin in Second Stage Revision Arthroplasty of the Hip Phase 4
Completed NCT02534753 - A Pharmacokinetics Study of Intravenous Ascorbic Acid Phase 1
Completed NCT01682408 - Assess Pharmacokinetics of Fostamatinib in Fed and Fasted State in Combination With Ranitidine to Assess Bioavailability Phase 1
Completed NCT01976078 - Development of Voriconazole Pharmacokinetics and Metabolism in Children and Adolescents N/A
Completed NCT01636024 - To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594 Phase 1
Completed NCT01208155 - Study in Healthy Males to Assess Bioavailability of 4 Different Fostamatinib Tablets Phase 1
Completed NCT01415102 - A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Inhaled Doses Of PF-05212372. Phase 1
Completed NCT01214941 - Effect of Itraconazole and Ticlopidine on the Pharmacokinetics and Pharmacodynamics of Oral Tramadol Phase 4
Completed NCT01260025 - Tolerability and Pharmacokinetics of M2ES in the Treatment of Advanced Solid Tumor Phase 1
Completed NCT01055964 - a Comparative Pharmacokinetic Study of Two Oral Formulations of Tacrolimus in Renal Allograft Recipients Phase 3
Completed NCT01276119 - The First Clinical Study to Test Safety, Blood Levels and Other Effects of CDP6038 in Healthy Males Phase 1
Completed NCT00747721 - Pharmacokinetics of Dexmedetomidine During Prolonged Infusion in ICU Phase 1
Completed NCT00983242 - Drug-Drug Interaction Between Colchicine and Verapamil ER Phase 1
Completed NCT00730145 - A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis Phase 1
Completed NCT00984009 - A Drug-Food Interaction Study Between Colchicine and Grapefruit Juice Phase 1
Completed NCT00746499 - Pharmacokinetic Study of Raltegravir in Healthy Premenopausal Women. Phase 1

External Links